BioWorld

Feb. 1, 2002

CuraGen, Bayer Advance Four Compounds Through Screening

One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today) Read More

ViaCell Files For $115M IPO To Fund Clinical Trials, R&D

One Unfertilized Egg From Single Female Primate Donor Produced Broad Spectrum Of Progeny Cells

Digene Raises $15M Through Stock Sale To Acqua Wellington

AltaRex Reanalyzes OvaRex IIb Results, Reaches Significance

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...